For Immediate ReleaseChicago, IL – June 9, 2025 – Today, Zacks Equity Research discusses Penumbra (PEN) , Integer Holdings (ITGR) and AngioDynamics (ANGO) .Industry: Medical InstrumentsLink: https://www.zacks.com/commentary/2487141/3-medical-instruments-stocks-winning-big-with-genai-amid-global-gloomOver the past year, advancements in artificial intelligence (AI) and predictive analytics have rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and p ...

ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii. Penumbra Introduces the Ruby® XL System – the Longest, Largest, and Sof ...

Penumbra (PEN) 2025 Conference June 04, 2025 09:55 AM ET Speaker0 Okay. So we're ready to kick off. This is the fireside chat with Penumbra. My name is Mike Sarcone. I'm one of the analysts on the US medical supplies and devices team. And with us from the company today, we have Adam El Seltzer. He's co founder, president, chairman, and CEO. We've also got Jason Mills, director of strategy. And Cecilia Furlong, who is a director of business Development, is also here with us. So team, thank you for joining us ...

Summary of Penumbra (PEN) FY Conference Call - June 03, 2025 Company Overview - **Company**: Penumbra, a medical technology company based in Alameda, California, specializing in thrombectomy and embolization products [5][6] - **Employees**: Over 4,500 [6] - **Market Position**: Penumbra is recognized as a leading player in the VTE (Venous Thromboembolism) market, with significant growth potential [2][3] Industry Insights - **VTE Market Growth**: The VTE market is experiencing a shift towards mechanical thrombectomy products, with a projected market growth of 20% in 2025 and beyond [3][48] - **Competitor Challenges**: One of Penumbra's largest competitors is facing integration issues, presenting an opportunity for Penumbra to capture market share [3] - **Clinical Data Impact**: Upcoming clinical data is expected to influence societal guidelines and increase the adoption of mechanical thrombectomy [3] Product Innovations - **CAPT Platform**: A new CAPT platform for neuro is anticipated to drive growth, similar to previous innovations in VTE [3] - **Thrombectomy Technology**: Penumbra's current technology, CABT (Computer Assisted Vacuum Thrombectomy), enhances the effectiveness of clot removal [14][15] - **Device Efficiency**: Recent advancements have reduced device time for clot removal to as low as two minutes, significantly improving patient outcomes [21][22][26] Financial Performance - **Revenue Growth**: Penumbra has reported over 40% growth in VTE for several quarters, with expectations to maintain this momentum [46][48] - **China Market Impact**: Revenue from China has declined due to tariffs and economic conditions, which could affect overall growth projections [44] Strategic Focus - **Four-Pronged Strategy**: The company aims to focus on innovation, commercial team investment, market access, and margin expansion to drive future growth [33][35] - **Market Access Initiatives**: Penumbra is working with hospitals to demonstrate the clinical and financial benefits of their products, aiming to increase treatment rates for DVT and PE [38][39] Key Takeaways - **Patient Impact**: Penumbra's products are designed to significantly improve patient outcomes, with a focus on treating a larger percentage of potential cases [52][53] - **Long-Term Growth Potential**: The combination of innovative products, market access strategies, and a growing VTE market positions Penumbra for sustained growth in the coming years [3][48][53]

A month has gone by since the last earnings report for Penumbra (PEN) . Shares have lost about 10.6% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, fre ...

Penumbra’s (PEN) shares have registered impressive momentum in the past year, with shares rallying 35.9%. It has outperformed the industry’s 13.3% decline. However, the S&P 500 composite has gained 11.6% during the same period.Carrying a Zacks Rank #3 (Hold) at present, the renowned thrombectomy company benefits from the strong customer uptake of its Lightning Bolt and Flash lines in both the U.S. and international markets. Penumbra’s overseas operations show strong potential for growth and profit improveme ...

Core Insights - Penumbra, Inc. is scheduled to present at multiple investor conferences in June 2025, showcasing its commitment to engaging with investors and stakeholders [1][2]. Group 1: Upcoming Events - The company will present at the William Blair 45th Annual Growth Stock Conference on June 3, 2025, at 3:00 PM ET [2]. - The Jefferies Global Healthcare Conference is scheduled for June 4, 2025, at 9:55 AM ET [2]. - The Truist Securities MedTech Conference will take place on June 17, 2025, at 10:00 AM ET [2]. Group 2: Company Overview - Penumbra, Inc. is recognized as the world's leading thrombectomy company, focusing on innovative technologies for medical conditions like ischemic stroke and venous thromboembolism [3]. - The company's portfolio includes computer-assisted vacuum thrombectomy (CAVT), aimed at efficiently removing blood clots [3]. - Penumbra operates in over 100 countries, supporting healthcare providers to enhance patient outcomes and quality of life [3].

Summary of Penumbra (PEN) 2025 Conference Call Company Overview - **Company**: Penumbra, Inc. (PEN) - **Market Cap**: Increased from $1 billion to approximately $11.12 billion over the past decade [3][4] Core Industry Insights - **Industry**: Medical Devices, specifically focusing on thrombectomy and stroke treatment - **Market Dynamics**: The competitive landscape has evolved, with Penumbra transitioning from competing against other companies to focusing on internal innovation [5][6][15] Key Points and Arguments 1. **Innovation as a Growth Driver**: Penumbra attributes its success to continuous innovation and improvement of its products, particularly in thrombectomy technology [4][5] 2. **Digital Transformation**: The company is entering a digital age, enhancing its product capabilities through software improvements rather than solely hardware changes [6][10] 3. **Market Leadership**: Penumbra remains a dominant player in the aspiration thrombectomy market, despite increased competition from private companies [15][16] 4. **Challenges in Stroke Treatment**: Structural issues in the healthcare system hinder patient access to treatment, impacting growth in the stroke market [17][18] 5. **Regulatory Process**: The company is currently in the FDA review process for its Thunderbolt product, with no significant updates on the timeline for approval [22][23] 6. **Market Access Strategy**: Penumbra is working on demonstrating the clinical and economic benefits of its products to hospitals, aiming to change treatment protocols [50][51][52] 7. **Growth in VTE Market**: The company has seen a 42% growth rate in the US venous thromboembolism (USVT) market, driven by peer recommendations among physicians [43][48] 8. **China Market Impact**: Revenue from China has significantly decreased, impacting overall guidance, but the company remains optimistic about future opportunities [65][67] Additional Important Insights - **Quality of Life Measures**: The company emphasizes the importance of quality of life in its clinical trials, particularly for patients undergoing treatment for intermediate pulmonary embolism [59][61] - **Product Launches**: Excitement around new product launches, such as Ruby XL, indicates ongoing innovation and market engagement [68][69] - **Economic Considerations**: The economic benefits of using Penumbra's products over traditional treatments are highlighted, suggesting a potential shift in hospital protocols [52][53] This summary encapsulates the key insights and strategic directions discussed during the conference call, reflecting Penumbra's focus on innovation, market dynamics, and growth opportunities in the medical device industry.

Company Overview - Penumbra, Inc. is the world's leading thrombectomy company focused on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia [2] - The company's portfolio includes computer assisted vacuum thrombectomy (CAVT), aimed at removing blood clots efficiently and safely [2] - Penumbra supports healthcare providers in over 100 countries, working to improve patient outcomes and quality of life [2] Upcoming Event - Penumbra's management team is scheduled to present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 6:00 PM ET [1] - A webcast of the presentation will be available on the company's website for at least two weeks following the event [1]

Core Insights - Penumbra Inc reported better-than-expected first-quarter 2025 earnings and reaffirmed its 2025 forecast, leading to an increase in stock price [1][5] Financial Performance - Revenue from global thrombectomy products reached $226.5 million in Q1 2025, marking a 20.7% increase, or 21.2% in constant currency [1] - U.S. thrombectomy revenue was $187.9 million, reflecting a year-over-year increase of 25.0% [1] - Revenue from global embolization and access products grew to $97.6 million, a 7.3% increase, or 8.1% in constant currency [2] - U.S. embolization and access products revenue increased by 16.2% to $68.97 million [2] - Operating income was $40.4 million, with Q1 net income at $39.2 million and adjusted EBITDA of $59.6 million, resulting in margins of 12.1% and 18.4% respectively [2][6] - Total sales for the quarter were $324.1 million, up 16.3% year over year, exceeding the consensus estimate of $315.66 million [6] Guidance and Outlook - Penumbra reaffirmed its fiscal year 2025 sales guidance of $1.34 billion to $1.36 billion, aligning with the consensus of $1.35 billion [3] - The company increased its guidance for U.S. thrombectomy franchise growth to 20% to 21% year over year, up from the previous estimate of 19% to 20% [7] - Guidance for gross margin expansion is set at a minimum of 100 basis points in 2025, targeting over 67% for the full year, and operating margin expansion to 13%-14% of revenue for 2025 [7] Analyst Insights - William Blair noted that Penumbra is well-insulated from tariff impacts due to its domestic manufacturing and sourcing of 75% of raw materials in the U.S. [4] - Multiple analysts maintained positive ratings on Penumbra, with price targets raised: Stifel from $301 to $318, Truist from $315 to $330, Wells Fargo from $305 to $315, Baird from $316 to $325, and UBS from $320 to $330 [8]